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ECONOMIC AND OUTCOMES STUDY 
RESULTS FOR PULMONARY DISORDERS AND 
INFECTIOUS DISEASE
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BACKGROUND: Current asthma guidelines advocate
early therapy with inhaled corticosteroids to reduce bron-
chial inflammation. The aim of the present study was to
examine the association between compliance with preven-
tive therapy (inhaled corticosteroids, sodium cromogly-
cate, and nedocromil) and hospitalization for asthma.
METHODS: From the Tayside MEMO record-linkage
database we identified a cohort of subjects receiving pre-
scriptions for inhaled corticosteroids. Subjects aged 12–45
years, with at least 3 months’ exposure during the period
August 1992 to December 1994, were included in the
study. Compliance was estimated by calculating the max-
imum number of days for which a subject could have
taken an inhaled corticosteroid. In the 3-month exposure
window, subjects with 90 days therapy were designated
as “compliant,” those with 1–89 days were defined to be
“partially compliant,” and those with zero days were “non-
compliant.”
RESULTS: Of the subjects, 4535 provided calculable
compliance, with a total of 88 occurrences of hospitaliza-
tion for asthma. The proportion of subjects with hospital-
ization was 9% for compliant subjects, 3% for partially
compliant subjects, and 1% for noncompliant subjects.
The odd-ratios (ORs) for partial compliance versus com-
pliance were: 0.34 (95% confidence interval [CI] 0.19–
0.62) and 0.10 (95% CI 0.05–0.19) for noncompliance
versus compliance. The association between compliance
and hospitalization disappeared after adjustment for
number of doses of beta-agonists and the number of types
of medication taken for relief of asthma.
CONCLUSION: As the degree of compliance increased,
the incidence of hospitalization with asthma also in-
creased. However, this association was probably due to
worsening symptoms leading to better compliance with
all medications. The results suggest that patients with
asthma take their preventive medications more regularly
when the condition is worsening.
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OBJECTIVE: Oral ciprofloxacin is an antibiotic com-
monly used for ambulatory treatment of exacerbations of
chronic airway diseases (ECAD). However, its clinical su-
periority over other antibiotics remains to be proven.
Randomized clinical trials in which efficacy was mea-
sured with bacterial eradication and disappearance of
symptoms provided inconclusive results.
METHODS: Using the administrative databases of the
Quebec Health Insurance Plan, we assessed the effective-
ness of oral ciprofloxacin in the ambulatory treatment of
ECAD among patients aged over 65 years. Within a co-
hort of 10,820 subjects (mean age 73 years) followed
from 1989 to 1996, we performed a case-control analysis
to determine whether oral ciprofloxacin prevents hospi-
talizations for ECAD.
RESULTS: During the first 7 days of therapy, 465 cases
of hospitalization for ECAD occurred, while 175 cases
occurred after the seventh day of therapy. After adjusting
for markers of disease severity, we found that users of
oral ciprofloxacin were less likely to be hospitalized than
users of other antibiotics during the early part of therapy
(1–7 days) (rate ratio  0.6; 95% CI 0.4–1.0). However,
after 7 days of therapy we found that users of ciprofloxa-
cin were more likely to be hospitalized for ECAD (rate
ratio  1.7; 95% CI 1.1–3.3).
CONCLUSION: Ciprofloxacin was found to be associ-
ated with a reduction in hospitalizations for ECAD com-
pared with other antibiotics early in the course of ther-
apy, but with an increase in hospitalizations after 7 days
of therapy. The lack of effectiveness in the later part of
therapy is likely due, at least in part, to confounding by
indication.
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OBJECTIVE: Concepts of quality of life are gaining in-
creasing significance as measures of outcome, both in med-
icine as well as in economics. Therefore—particularly for
chronic illnesses such as asthma—instruments are nec-
essary which make the influence of the illness on the
daily life of the patients measurable from a subjective
point of view. One such questionnaire is the Fragebogen
zur Asthmaqualität (FLA), a disease-specific instrument for
measuring the quality of life of asthma patients. This ques-
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tionnaire was supplemented with a generic instrument, the
EuroQol. The aim of the study was to measure the quality
of life depending upon severity level of the illness.
METHODS: Adult asthma patients treated in 23 pneu-
mologic ambulatory care units were randomly selected
and asked to fill out both the FLA and the EuroQol ques-
tionnaires. Separate analyses of the results were carried
out for each patient severity level; they covered the aver-
age values of the subscales, the correlation and the inter-
nal reliability of the questionnaires.
RESULTS: The quality of life of asthma patients corre-
lates strongly to the respective severity level of the illness.
This applies to all the examined dimensions of health-
related quality of life. The patients of level 3 (serious
asthma) in particular achieve values far below average
when compared to the total population (42 out of 100,
according to EuroQol). By contrast, the subjective quality
of life of asthmatics in level 1 is only slightly reduced. The
correlation of the FLA subscales as well as of the Euro-
Qol values is high (0.74–0.97). 
CONCLUSIONS: The study makes clear that illness pro-
gression is associated with high losses of quality of life for
the patient. From a health-economic point of view, this is
important for the calculation of so-called intangible costs,
which are often not quantified in studies on the cost of
disease.
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Childhood asthma is a disease that affects not only pa-
tients but also the quality of life of their parents and care-
givers. The PACQLQ is a 13-item scale that was devel-
oped in English to measure this impact. Prior to use in an
international trial, the original questionnaire underwent
cultural adaptation giving rise to 19 language versions.
This cultural adaptation process involved the recruitment
of a QoL specialist in each country as supervisor of the
translation process. First, each QoL specialist discussed
the concepts of the original instrument with the developer
(EFJ). Native speakers then produced two independent
forward translations. These were reconciled and back-
translated twice into English. Finally, the translations
were tested on a sample target population through in-
depth interviews conducted by the senior translator and
asthma clinicians. Translation problems included finding
conceptual equivalents for typical English expressions
and constructions. For example, “to feel frustrated,” “to
feel upset,” and “irritable” either had no literal equiva-
lent or led to misinterpretation in some languages. The
item “Did you feel angry that your child has asthma?”—
the content of which was found inappropriate in most
countries—had to be changed to reflect an emotion more
commonly experienced by parents. Finally, the design and
the mode of administration of the questionnaire was some-
what problematic in countries where people are not used
to completing questionnaires and have a low level of edu-
cation. Before use in an international trial, rigorous cul-
tural adaptation was essential to produce cross-culturally
valid language versions of the PACQLQ. The comparison
of answers across countries will clarify whether the im-
pact of asthma on parents or caregivers is similar in all
countries. Measurement properties will also have to be
confirmed once clinical data are available.
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Antibiotic resistance is a growing problem in all coun-
tries. However, because the precise role of community
antibiotic prescribing is undefined, practitioners attribute
the problem to overuse of antibiotics by others.
METHODS: Case-control design with incident urine sam-
ples (no sample in previous 6 months) from the population
of Tayside from 1 July 1993 to 31 December 1995. Cases
were subjects from whom trimethoprim-resistant gram-
negative bacteria (TR) were isolated. Controls were sub-
jects whose samples grew trimethoprim-sensitive gram-
negative bacteria (TS) or showed no bacterial growth
(NG). Exposure to risk factors in each group was deter-
mined from the MEMO and DARTS record-linkage data-
bases. Logistic regression was used to identify independent
risk factors. Demographic variables were age, sex, socio-
economic status, and diabetes mellitus. Exposure variables
(in the previous 6 months) were hospitalization and dis-
pensing of the following drugs from community pharma-
cies: antibiotics, corticosteroids or estrogens.
RESULTS: Of the 9362 incident urine samples used, 380
were TR, 1073 TS, and 7909 NG. The most important
risk factors were: exposure to trimethoprim (odds ratio
[OR] 3.08; 95% CI 2.48–3.81) or other antibiotics (OR
1.43; CI 1.14–1.80). Additional independent risk factors
were age (OR 1.28 for every 10 years after the first dec-
ade; CI 1.23–1.35) and prior hospitalization (OR 1.38;
CI 1.07–1.79). However, 35% of the TR group had not
been exposed to antibiotics or been hospitalized in the
previous 6 months.
CONCLUSION: There was a strong link between trime-
thoprim resistance and community prescribing of trime-
thoprim or other antibiotics. However, prior hospitaliza-
tion was an independent risk factor, and 35% of cases
were not associated with either risk factor. These data
suggest that antibiotic resistance is multifactorial.
